The company has $400 million, enough cash to potentially build off results from an early-stage leukemia yet this quarter.
Companies working on new medicines to treat obesity and a new approach to using artificial intelligence in science labs are ...
Genentech is laying off 143 workers in the South San Francisco drugmaker’s third layoff round since April 2024. The company, a biotech stalwart owned by the pharmaceutical giant Roche, announced the ...
Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid ...
A lector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...
US and European pharmaceutical firms are licensing new drug candidates developed in China at an increasing clip. Some industry watchers see opportunity in China’s biomedical market; others see a ...
An international biotechnology company that is headquartered in Connecticut is laying off 68 employees in the state. PerkinElmer U.S. LLC is permanently closing its manufacturing facility at 710 ...
Exelixis, a high-flying biotech company that creates anti-cancer drugs in Alameda, is laying off 130 workers. Exelixis had, like others in the industry, hired heavily during and after the pandemic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback